Study of DS-1123a in Advanced Solid Tumours
This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.
Advanced Solid Malignant Tumors
DRUG: DS-1123
Maximum concentration (Cmax), Cycles 1, 2 : Days 1,2, 4, 8, 15|Number and severity of treatment emergent adverse events (TEAEs), Day 1 to Day 31|Time of maximum concentration (Tmax), Cycles 1, 2: Days 1,2, 4, 8, 15|Elimination rate constant (Kel), Cycles 1, 2: Days 1,2, 4, 8, 15|area under the curve AUClast, pharmacokinetics profile, Cycles 1, 2: Days 1,2, 4, 8, 15|Area under the curve (AUCtau), Cycles 1, 2: Days 1,2, 4, 8, 15|Area under the curve (AUCinf), Cycles 1, 2: Days 1,2, 4, 8, 15|Half-life (T1/2), Cycles 1, 2: Days 1,2, 4, 8, 15|Drug clearance (CL), Cycles 1, 2: Days 1,2, 4, 8, 15|Volume of distribution (Vz), Cycles 1, 2: Days 1,2, 4, 8, 15|Mean residence time (MRTinf), Cycles 1, 2: Days 1,2, 4, 8, 15
DS-1123a antibody, DS-1123a antibody on Cycle 1: Days 1,15; Cycles 2 and on: Day 1, Stop date, final follow-up date, Cycle 1: Days 1,15; Cycles 2: Day 1; Stop date, final follow-up date|Change in Cytokines expression, Change in DS-1123a biomarkers Cytokines expression on Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2, Cycle 1: Days 1, 2, 15, 16; Cycle 2: Days 1, 2
This is an open-label study to evaluate the safety, tolerability, and pharmacokinetics of DS-1123a in Japanese subjects with advanced solid tumors.